PIK3CG and diffuse large B-cell lymphoma: This is consistent with the study of Griner et al., who described a high-throughput screening platform that could rapidly and systematically identify synergistic, additive, and antagonistic drug combinations and found that the combination of ibrutinib with various PI3K pathway inhibitors, such as MK-2206, CAL-101, BKM-120, BEZ-235, GDC-0941, GDC-0980, everolimus, and PRT-060318, had either synergistic or additive effects on the inhibition of human ABC-DLBCL line TMD8 [28].